Business
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (formerly Galecto, Inc.) (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamental
About this update from Damora Therapeutics, Inc.
[{"type":"image","alt":"Damora Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Damora Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/39e722f9d4ca06880ac12b134774dc44"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y_f1Ey89t1gW3ao7vlUd2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNA--/https://media.zenfs.com/en/globenewswire.com/39e722f9d4ca06880ac12b134774dc44","width":300,"height":74}},"lazy":false},{"type":"text","content":"-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 --","length":133,"tagName":"p"},{"type":"text","content":"-- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 --","length":181,"tagName":"p"},{"type":"text","content":"BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (formerly Galecto, Inc.) (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights.","length":358,"tagName":"p"},{"type":"text","content":"“At Damora Therapeutics, we strive to rapidly bring forward best-in-class medicines to dramatically improve the lives of patients with blood disorders. Today, we are well on the path to achieving our goal based on recent progress, including the acquisition of three highly innovative mutant calreticulin (mutCALR) targeted therapies and two oversubscribed financings extending our cash runway into Phase 3 development,” said Sherwin Sattarzadeh, Chief Operating Officer of Damora Therapeutics. “With this strong foundation in place, we are on track to submit an IND or CTA for our lead program DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) by mid-2026 and subsequently deliver important clinical datasets next year.”","length":750,"tagName":"p"},{"type":"text","content":"Corporate Highlights","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Completed the acquisition of Damora Therapeutics in November 2025, adding a pipeline ...